Published in Cancer Treat Res on January 01, 1992
1,2,3,4,6-Penta-O-galloylglucose within Galla Chinensis Inhibits Human LDH-A and Attenuates Cell Proliferation in MDA-MB-231 Breast Cancer Cells. Evid Based Complement Alternat Med (2015) 0.79
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
The development of human benign prostatic hyperplasia with age. J Urol (1984) 8.29
Identification of a nuclear protein matrix. Biochem Biophys Res Commun (1974) 5.41
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res (2001) 4.12
A fixed site of DNA replication in eucaryotic cells. Cell (1980) 3.78
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res (2001) 3.37
Nuclear protein matrix: association with newly synthesized DNA. Science (1975) 3.27
Nuclear matrix. Isolation and characterization of a framework structure from rat liver nuclei. J Cell Biol (1977) 3.26
Supercoiled loops and eucaryotic DNA replicaton. Cell (1980) 3.24
Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol (1999) 3.19
Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst (1993) 2.76
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology (2000) 2.35
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol (2001) 2.32
Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl (1989) 2.12
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am (1997) 2.07
The role of the nuclear matrix in the organization and function of DNA. Annu Rev Biophys Biophys Chem (1986) 2.07
Prostate-specific antigen: what's new in 1997. Oncology (Williston Park) (1997) 2.06
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology (1995) 2.00
DNA packaging and organization in mammalian spermatozoa: comparison with somatic cells. Biol Reprod (1991) 1.99
Considerations in the isolation of rat liver nuclear matrix, nuclear envelope, and pore complex lamina. Exp Cell Res (1981) 1.99
Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol (1996) 1.98
Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res (1998) 1.92
Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol (1997) 1.90
Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res (1996) 1.87
Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol (1994) 1.87
Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res (1981) 1.80
Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology (1997) 1.79
Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol (2000) 1.72
The prostate: an increasing medical problem. Prostate (1990) 1.67
The specific binding of estrogens and androgens to the nuclear matrix of sex hormone responsive tissues. J Biol Chem (1980) 1.66
Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiol Biomarkers Prev (1996) 1.64
Stem cell features of benign and malignant prostate epithelial cells. J Urol (1998) 1.62
Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol (1998) 1.60
Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol (1998) 1.57
OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology (1995) 1.56
Fourier analysis of cell motility: correlation of motility with metastatic potential. Proc Natl Acad Sci U S A (1989) 1.55
The epidemiology of prostate cancer in Jamaica. J Urol (1998) 1.53
Future prospects in prostate cancer. Prostate (1999) 1.53
Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol (1998) 1.50
Ablation of renal tumors in a rabbit model with interstitial saline-augmented radiofrequency energy: preliminary report of a new technology. Urology (1999) 1.49
Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol (1997) 1.46
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology (2000) 1.44
A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome. J Cell Sci Suppl (1984) 1.43
Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch Biochem Biophys (1968) 1.43
Identification and characterization of circulating prostate carcinoma cells. Cancer (2000) 1.41
The nuclear protein matrix: isolation, structure, and functions. Adv Enzyme Regul (1976) 1.41
Comparison of robotic versus human laparoscopic camera control . J Urol (1995) 1.40
Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci (1998) 1.39
Interaction between tetraethylthiuram disulfide and the sulfhydryl groups of D-amino acid oxidase and of hemoglobin. J Biol Chem (1966) 1.38
Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res (1994) 1.38
The effect of hospital volume on cancer control after radical prostatectomy. J Urol (2005) 1.36
Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res (1991) 1.35
Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol (1998) 1.34
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol (2000) 1.33
Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Cancer Res (1988) 1.32
The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol (1988) 1.32
Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature (1986) 1.31
Partial nephrectomy: technique, complications and pathological findings. J Urol (1995) 1.30
Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer (1997) 1.29
Nuclear-cytoskeletal interactions: evidence for physical connections between the nucleus and cell periphery and their alteration by transformation. J Cell Biochem (1992) 1.27
Correlation of nuclear morphometry with progression of breast cancer. Cancer (1991) 1.26
Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology (2001) 1.24
Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res (1989) 1.24
Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res (1996) 1.23
The relationship of the nuclear matrix to cellular structure and function. Adv Enzyme Regul (1978) 1.23
Heredity and prostate cancer: a study of World War II veteran twins. Prostate (1997) 1.22
The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J Urol (1989) 1.20
Comparison of spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest (1979) 1.20
The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res (1998) 1.20
Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate (1999) 1.20
A sensitive radioassay for sulfhydryl groups with tetraethylthiuram disulfide. J Biol Chem (1966) 1.20
Influence of radical prostatectomy on serum hormone levels. J Urol (1998) 1.19
Bioimpedance: novel use of a minimally invasive technique for cancer localization in the intact prostate. Prostate (1999) 1.19
New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology (1999) 1.18
The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol (2000) 1.17
Telementoring of laparoscopic procedures: initial clinical experience. Surg Endosc (1996) 1.17
Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology (2001) 1.16
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol (1999) 1.16
In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis (1997) 1.16
Nuclear structure and the three-dimensional organization of DNA. J Cell Biochem (1991) 1.16
Prostatic growth rate determined from MRI data: age-related longitudinal changes. J Androl (1999) 1.14
A novel M(r) 32,000 nuclear phosphoprotein is selectively expressed in cells competent for self-renewal. Cancer Res (1993) 1.12
Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol (1996) 1.11
Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology (1999) 1.11
Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res (1978) 1.11
An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology (1998) 1.10
Incidental non-Hodgkin's lymphoma in patients with localized prostate cancer. Urology (1999) 1.10
Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol (2013) 1.10
A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology (2000) 1.10
Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol (1998) 1.09
Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. Urology (2000) 1.07
HE2beta and HE2gamma, new members of an epididymis-specific family of androgen-regulated proteins in the human. Endocrinology (2000) 1.07
Adenocarcinoma of the prostate in men younger than 40 years of age: diagnosis and treatment with emphasis on radical prostatectomy findings. Urology (1999) 1.07
The interaction of natural and synthetic polyanions with mammalian nucleo. I. DNA synthesis. Biochim Biophys Acta (1970) 1.06